Spyre Therapeutics (NASDAQ: SYRE) announced inducement stock option awards totaling 70,200 shares to five non-executive employees, approved April 1, 2026, under the 2018 Equity Inducement Plan. The options have a 10-year term and an exercise price of $48.90 (Nasdaq close April 1, 2026).
Vesting is one-fourth after the first anniversary of each employee’s start date and thereafter monthly at one-forty-eighth, subject to continuous service and the terms of the 2018 Plan. Grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – SYRE
+2.94%
+2.94%Session close to close
In the Apr 6 session, SYRE gained 2.94%, reflecting a moderate positive market reaction.
This announcement details routine inducement awards totaling 70,200 stock options for five new emplo...
Analysis
This announcement details routine inducement awards totaling 70,200 stock options for five new employees, with a $48.90 exercise price, 10-year term, and standard vesting over four years. It follows a series of clinical and corporate updates that have previously coincided with positive stock moves. Investors may track how ongoing hiring, upcoming SKYLINE and SKYWAY readouts, and the effective $500,000,000 shelf and $154,059,875 ATM capacity interact with Spyre’s cash needs and development plans.
Key Figures
Inducement option shares:70,200 sharesEmployees granted:5 employeesOption exercise price:$48.90 per share+5 more
8 metrics
Inducement option shares70,200 sharesAggregate stock options granted to five non-executive employees
Employees granted5 employeesRecipients of inducement awards under the 2018 Plan
Option exercise price$48.90 per shareExercise price equal to Apr 1, 2026 Nasdaq close
Option term10-year termDuration of inducement stock options granted
Initial vesting25% after 1 yearOne-fourth vests on first anniversary of start date
Ongoing vesting1/48th monthlyRemainder vests monthly thereafter, subject to service
Shelf registration size$500,000,000Total securities under S-3 shelf dated Feb 19, 2026
ATM capacity$154,059,875Common stock under TD Cowen at-the-market agreement
Presented SPY003 interim data and combo superiority signals at ECCO Congress.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news, especially clinical and corporate updates, has often coincided with positive price reactions for SYRE.
Recent Company History
Over recent months, Spyre has reported multiple catalysts. The Feb 19, 2026 earnings update highlighted $756.5 million in cash and plans for six 2026 proof-of-concept readouts, with shares rising 14.28%. Clinical and scientific updates, such as SKYWAY timeline acceleration on Mar 16, 2026 and ECCO presentations on Feb 18, 2026, also saw positive reactions. Even a prior inducement grant on Mar 6, 2026 produced a mild gain. Today’s inducement awards fit a pattern of frequent equity- and pipeline-related disclosures.
"approved the grant of stock options to purchase an aggregate of 70,200 shares"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
equity inducement awardsfinancial
"shares of common stock of Spyre to five non-executive employees as equity inducement awards"
Equity inducement awards are special stock-based rewards given to new employees to encourage them to join a company or stay long-term. They are like signing bonuses paid with company shares instead of cash, helping motivate employees to contribute to the company's success.
Nasdaq Listing Rule 5635(c)(4)regulatory
"material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
exercise pricefinancial
"a 10-year term and an exercise price equal to $48.90, the closing price per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 70,200 shares of common stock of Spyre to five non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options were approved on April 1, 2026 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options were granted with a 10-year term and an exercise price equal to $48.90, the closing price per share of Spyre's common stock as reported by Nasdaq on April 1, 2026. The options granted to the employees shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Spyre through the applicable vesting dates. The stock options are subject to the terms of the 2018 Plan.
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.
For more information, please visit http://spyre.com.
For Investors: Eric McIntyre SVP of Finance and Investor Relations Spyre Therapeutics Eric.mcintyre@spyre.com
FAQ
What stock option awards did Spyre (SYRE) grant on April 1, 2026?
Spyre granted stock options to purchase 70,200 shares to five non-executive employees. According to the company, the awards were approved April 1, 2026 as inducement grants under the 2018 Equity Inducement Plan.
What is the exercise price and term of the SYRE inducement options granted April 1, 2026?
The options carry a $48.90 exercise price and a 10-year term. According to the company, $48.90 equals Spyre's Nasdaq closing price on April 1, 2026 used to set the strike.
How do the SYRE inducement option grants vest for employees?
Options vest 25% after the first anniversary, then monthly at 1/48th thereafter. According to the company, vesting is subject to each employee's continuous service through the applicable vesting dates.
Were the SYRE option grants compliant with Nasdaq rules?
Yes, the awards were approved as inducement grants under Nasdaq Listing Rule 5635(c)(4). According to the company, the grants were material to each employee's acceptance of employment per the Nasdaq rule.
Who received the inducement awards and under which plan were they granted for SYRE?
Five non-executive employees received the options, granted under the Spyre 2018 Equity Inducement Plan. According to the company, the grants were made as equity inducements to facilitate new hires.
